Search Results
Aug 10, 2026, 16:02 ET Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
approximately 70% within the first month of dosing. These reductions were deeper than those reported for BAFF/APRIL inhibitors, APRIL inhibitors, and CD38 inhibitors at comparable early time points. Reductions in Gd-IgA1 were associated with increases in eGFR, decreases in spot UPCR, and resolution of
More news about: Biohaven Ltd.
Aug 08, 2026, 03:46 ET RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias
CAR-T officially advancing into clinical development. RXIM002 is an investigational product employing tLNP encapsulated circRNA that encodes a CD19‑targeting chimeric antigen receptor (CAR) for the treatment of autoimmune cytopenias. By delivering circRNA to T cells in vivo, RXIM002 enables
More news about: RiboX Therapeutics Ltd.
Aug 06, 2026, 21:51 ET Charter Announces Pricing Terms For Debt Exchange Offers
$1,250,000,000161175CD4 / US161175CD447
More news about: Charter Communications, Inc.
Aug 06, 2026, 07:30 ET ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
(ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Aug 06, 2026, 07:28 ET Charter Announces Results Of Early Tenders In Debt Exchange Offers And Amendment And Upsize of Debt Exchange Offers
$1,250,000,000161175CD4 /US161175CD447
More news about: Charter Communications, Inc.
Aug 06, 2026, 07:00 ET 再鼎醫藥公佈2026年第二季度財務業績及近期公司進展
預計於2027年上半年提供評估ZL-6201用於肉瘤和特定腫瘤患者的全球1a/b期研究劑量遞增部分的主要結果。ZL-1222（PD-1/IL-12）預計於2027年在美國提交一項新藥臨床試驗申請，並啟動一項全球1期研究。ZL-1311（MUC17/CD3）預計於2026年底前在美國提交一項新藥臨床試驗申請，並於2027年上半年啟動一項全球1期研究。區域管線有望獲得NMPA受理的上市許可申請
More news about: 再鼎醫藥
Aug 05, 2026, 20:00 ET Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
need[3-5]. As a PD-1/IL-2α-biased bispecific molecule, IBI363's dual antitumor mechanism—blocking PD-1 while stimulating tumor-specific CD8⁺ T cells (TST cells)—holds the promise of turning 'cold' tumors 'hot'. Early data for IBI363 in combination with bevacizumab in late-line treatment
More news about: Innovent Biologics
Aug 05, 2026, 09:07 ET Optiv Introduces Agentic Security Operations, Redefining Managed Security Services with the Power of Google Security Operations and Extensive Wiz Integration
Cloud continuously identifies and prioritizes cloud exposures, misconfigurations and attack paths. Wiz Code assesses critical risks across code and CI/CD, and Wiz Defend delivers real-time cloud detection and response. Together, they bring exposure and runtime context into a single console and directly
More news about: Optiv Security Inc.
Aug 04, 2026, 16:30 ET Chainguard Joins AWS Security Hub Extended as Supply Chain Partner
Chainguard Factory, the company's isolated build environment. This approach helps prevent malicious packages from reaching developers, CI/CD pipelines, and production systems."Open source is the foundation the world's software is built on. When that ecosystem gets compromised, the blast
More news about: Chainguard
Aug 04, 2026, 16:01 ET AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Polyangiitis (GPA)/Microscopic Polyangiitis (MPA)).DazodalibepDazodalibep is a fusion protein that inhibits CD40 ligand (CD40L).Two Phase 3 studies of dazodalibep in Sjögren's disease are underway. The first study is ongoing in patients with moderate-to-severe
More news about: Amgen
Aug 04, 2026, 09:00 ET OCUDU Ecosystem Foundation Welcomes Intel as a Premier Member, Strengthening Industry Collaboration for Open Source RAN
OCUDU Ecosystem Foundation's mission to enable Open Source RAN software through ecosystem collaboration, reference architectures, validation programs, CI/CD/CT infrastructure and operational best practices. Intel is dedicated to contributing its deep technical expertise to help shape open, standards-based
More news about: OCUDU Ecosystem Foundation
Aug 04, 2026, 07:00 ET Marengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion
T-cell engagement by enhancing antitumor potency in solid tumors while limiting the broad, indiscriminate T-cell activation associated with traditional CD3-directed T-cell engagers.This milestone demonstrates continued progress across the collaboration's multiple programs and further validates the
More news about: Marengo Therapeutics
Aug 03, 2026, 11:00 ET HiddenLayer Unveils Agent Harness Security to Protect AI-Powered Software Development at Runtime
the model and steer agents away from poisoned tool responses with corrective context. Where block-only enforcement would interrupt a long-running CI/CD pipeline and force a developer to step in, content-shaping lets the agent continue safely on its task and preserves the productivity gains AI coding
More news about: HiddenLayer
Aug 03, 2026, 08:00 ET cAMPfield Strengthens Leadership Team with Key Executive Appointments, Including Graham Heap, MD, PhD as President, R&D, to Advance Prifemilast into Global Phase 2 Development for Inflammatory Bowel Disease
MD joins as Head of Clinical Development and will lead clinical execution for the prifemilast program in ulcerative colitis (UC) and Crohn's disease (CD). Taylor Spector, PhD joins as Head of Medical Affairs and will lead medical strategy, evidence generation, scientific communications, and external engagement.
More news about: cAMPfield Therapeutics
Aug 03, 2026, 06:01 ET Appdome Introduces Appdome Test™ to Validate Every Protected Mobile App Release Against Real-World Deployments
brands, adding security earlier in the SDLC is the start. To really shift left, you also have to test each time you commit security code into the CI/CD pipeline," said Tom Tovar, Co-Creator and CEO of Appdome.Most mobile testing begins with a generic device bank, leaving brands to decide which
More news about: Appdome
Aug 02, 2026, 10:01 ET New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular
More news about: Specialised Therapeutics
Jul 31, 2026, 18:50 ET InsCorp, Inc. Reports Results for 2Q26
money market) increased 50% Y/Y and 5% linked-quarter ("LQ") to $445 million, or 49% of average deposits compared to 46% in 1Q26 and 38% in 2Q25. Average CD balance growth of -6% Y/Y and -8% LQ in 2Q26 resulted in a mix of 51% of average deposits, down from 54% a quarter ago and 62% a year ago. INSBANK's
More news about: INSBANK
Jul 31, 2026, 07:47 ET AbbVie Reports Second-Quarter 2026 Financial Results
Digestive Disease Week (DDW) Annual Meeting, AbbVie presented new data across its gastroenterology portfolio, including 18 abstracts in Crohn's disease (CD) and ulcerative colitis (UC). Presentations included real-world evidence and long-term findings that reinforced the efficacy, safety profile and durability
More news about: AbbVie
Jul 30, 2026, 16:06 ET Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).SELECT IMPORTANT SAFETY INFORMATIONWarnings and PrecautionsThrombocytopenia:
More news about: Karyopharm Therapeutics Inc.
Jul 30, 2026, 16:05 ET Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).SELECT IMPORTANT SAFETY INFORMATIONWarnings and PrecautionsThrombocytopenia:
More news about: Karyopharm Therapeutics Inc.
Jul 30, 2026, 10:31 ET Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
Clinical findings from Phase II studies, including APOLLO-CD and ARTEMIS-UC, demonstrated promising rates of clinical remission, endoscopic improvement, and sustained therapeutic benefit, paving the way for ongoing Phase III studies such as ARES-CD in Crohn's disease and ATLAS-UC in ulcerative colitis.Teva
More news about: DelveInsight Business Research, LLP
Jul 30, 2026, 07:00 ET CREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases
CRT-402 is a CD19-targeted, in vivo CAR-T therapy that reprograms a patient's own T cells directly within the body to deplete autoreactive B cells and drive disease into remission.
More news about: CREATE Medicines, Inc.
Jul 29, 2026, 13:14 ET GMP Biologics Market to Reach US$98.2 Bn by 2033 Accelerates with Biopharmaceutical Innovation - Persistence Market Research
Pediatric Cancer Biomarkers Market by Product Type (Alpha-fetoprotein (AFP), Neuron-specific enolase (NSE), CD19, Others), Indication (Leukemia, Neuroblastoma, CNS Tumors, Others), End-use (Hospitals, Diagnostic Laboratories, Others), and Regional Analysis for 2026
More news about: Persistence Market Research Pvt. Ltd.
Jul 29, 2026, 09:30 ET Evinced Harnesses Agentic Coding to Automatically and Reliably Fix Accessibility Problems
new set of tools to deploy that are transformationally easy to use.AutopilotAutopilot is an Evinced capability that runs inside CI/CD systems and alongside a customer's LLM. It detects accessibility defects, with the industry's most powerful detection, when code is submitted into the CI
More news about: Evinced
Jul 29, 2026, 08:59 ET Marshmellow Overcoat Channels Classic Rock Spirit on New Album 'Beat a Dead Horse'
donate half of its album and merchandise sales from the day.With 'Beat a Dead Horse' now available on all digital platforms, as well as vinyl and CD, Marshmellow Overcoat continues to deliver on its promise of classic rock and roll for today.Media Contact: Eric Alper Public Relations647-971-3742
More news about: Marshmellow Overcoat